Rezolute (NASDAQ:RZLT – Get Free Report) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Wednesday, Zacks reports.
RZLT has been the topic of a number of other research reports. Citizens Jmp raised their price objective on Rezolute from $11.00 to $15.00 and gave the company a “market outperform” rating in a research report on Tuesday, October 6th. Craig Hallum upgraded Rezolute from a “hold” rating to a “buy” rating and lifted their target price for the company from $4.00 to $7.00 in a research note on Tuesday, September 29th. Lake Street Capital boosted their target price on shares of Rezolute from $9.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. HC Wainwright increased their price target on shares of Rezolute from $5.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, September 25th. Finally, Cantor Fitzgerald upgraded shares of Rezolute from a “neutral” rating to an “overweight” rating in a report on Monday, October 5th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $11.67.
View Our Latest Report on RZLT
Rezolute Price Performance
NASDAQ RZLT opened at $4.20 on Wednesday. The company’s 50-day simple moving average is $4.05 and its two-hundred day simple moving average is $3.94. Rezolute has a one year low of $1.07 and a one year high of $11.16.
Rezolute (NASDAQ:RZLT – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Analysts predict that Rezolute will post -0.66 earnings per share for the current year.
Hedge Funds Weigh In On Rezolute
Several hedge funds have recently made changes to their positions in the company. Auxano Advisors LLC acquired a new stake in shares of Rezolute during the second quarter worth about $52,000. Sequoia Financial Advisors LLC purchased a new stake in Rezolute in the second quarter valued at approximately $75,000. WINTON GROUP Ltd acquired a new position in Rezolute in the 2nd quarter worth approximately $88,000. Integrated Wealth Concepts LLC acquired a new position in Rezolute in the 2nd quarter worth approximately $143,000. Finally, Hsbc Holdings PLC raised its position in Rezolute by 189.4% during the 1st quarter. Hsbc Holdings PLC now owns 36,939 shares of the company’s stock worth $113,000 after buying an additional 24,177 shares during the last quarter. 82.97% of the stock is owned by institutional investors and hedge funds.
About Rezolute
Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.
Further Reading
- Five stocks we like better than Rezolute
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
